HF
Clinical        trials have shown that beta-blocking agents increase left ventricular ejection       fraction and reduce left ventricular dimensions in patients with HF, indicating       regression of left ventricular remodelling.
Clinical        trials have shown that beta-blocking agents increase left ventricular ejection       fraction and reduce left ventricular dimensions in  @OBJECT$   @PREDICAT$   @SUBJECT$ , indicating       regression of left ventricular remodelling.